Valuation: Cerus Corporation

Market Cap 516M 450M 424M 386M 723M 49.42B 724M 5.07B 1.96B 25.18B 1.94B 1.89B 81.24B P/E 2026 *
-73.1x
P/E 2027 * -256x
Enterprise Value 521M 454M 428M 390M 730M 49.9B 731M 5.12B 1.97B 25.42B 1.96B 1.91B 82.03B EV / Sales 2026 *
2.09x
EV / Sales 2027 * 1.85x
Free-Float
96.39%
Yield 2026 *
-
Yield 2027 * -
1 day-3.40%
1 week+0.39%
Current month-3.03%
1 month-8.90%
3 months-5.19%
6 months+48.84%
Current year+24.27%
1 week 2.5
Extreme 2.5
2.68
1 month 2.45
Extreme 2.45
2.82
Current year 1.62
Extreme 1.62
3.47
1 year 1.38
Extreme 1.38
3.47
3 years 1.12
Extreme 1.12
3.47
5 years 1.12
Extreme 1.12
8.06
10 years 1.12
Extreme 1.12
8.87
Manager TitleAgeSince
Chief Executive Officer 51 2026-06-30
Chief Tech/Sci/R&D Officer 82 2015-06-30
Director of Finance/CFO 54 2009-05-03
Director TitleAgeSince
Chairman 59 2026-03-15
Director/Board Member 72 2014-03-23
Director/Board Member 51 2026-06-30
Date Insider Type Main position Quantity % Market Cap. Importance
8/17/26 Sell

General Counsel

-30,000 0.0150%
7/16/26 Sell

Chief Executive Officer

-16,666 0.0083%
7/1/26 Free

Chief Executive Officer

924,215 0.4613%
Change 5-day change 1-year change 3-year change Capi.($)
-3.40%+0.39%+75.34%+69.54% 516M
-0.34%-2.72%-27.24%-3.61% 105B
+0.15%-0.19%-23.27%-0.29% 11.63B
-1.39%-5.59%+93.52%+114.66% 9.52B
+4.88%+6.11%-49.75%-66.69% 4.22B
+2.01%+0.94%-26.40%+22.21% 2.39B
-1.38%+1.88%-5.21%-60.40% 2.19B
+1.06%+6.15% - - 1.96B
+1.56%+3.35%-18.85%-27.25% 1.55B
Average +0.35%+1.15%+2.27%+6.02% 15.46B
Weighted average by Cap. -0.16%-2.18%-18.37%+2.49%

Financials

2026 *2027 *
Net sales 249M 217M 205M 186M 349M 23.86B 350M 2.45B 944M 12.15B 936M 915M 39.22B 272M 237M 223M 203M 381M 26.01B 381M 2.67B 1.03B 13.25B 1.02B 997M 42.76B
Net income -8.77M -7.64M -7.2M -6.56M -12.29M -840M -12.31M -86.22M -33.23M -428M -32.93M -32.2M -1.38B -1.67M -1.45M -1.37M -1.25M -2.34M -160M -2.34M -16.39M -6.32M -81.34M -6.26M -6.12M -262M
Net Debt 5M 4.36M 4.11M 3.74M 7.01M 479M 7.02M 49.17M 18.95M 244M 18.78M 18.37M 787M -13M -11.33M -10.68M -9.72M -18.23M -1.25B -18.25M -128M -49.28M -634M -48.83M -47.75M -2.05B
Logo Cerus Corporation
Cerus Corporation is a biomedical products company. The Company is focused on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The INTERCEPT Blood System, which is based on its proprietary technology for controlling biological replication, is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. Its INTERCEPT Blood System is intended for use with blood components and certain of their derivatives: platelets, plasma, red blood cells and to produce INTERCEPT Fibrinogen Complex (IFC), and pathogen reduced plasma, cryoprecipitate reduced. The INTERCEPT Blood System for Cryoprecipitation uses its plasma system to produce IFC for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. In addition, the INTERCEPT Blood System for Cryoprecipitation is used to produce pathogen reduced plasma, cryoprecipitate reduced.
Employees
268
Date Price Change Volume
26-09-21 $2.560 -3.40% 1,915,017
26-09-18 $2.650 -0.38% 3,570,322
26-09-17 $2.660 +5.14% 2,463,559
26-09-16 $2.530 +1.20% 1,455,624
26-09-15 $2.500 -1.96% 1,019,084
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
2.560USD
Average target price
5.125USD
Spread / Average Target
+100.20%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CERS Stock
-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!